Danisco Animal Nutrition, a business subsidiary of DuPont Industrial Biosciences, will celebrate the launch of their advanced, highly bio-efficacious phytase into the Russian market by hosting a seminar at the upcoming VIV Russia.
The event (“Future of Feed and the Part Phytase Has to Play”) will highlight the Russian launch of Axtra® PHY and will be held on 20 May, 2015 from 13.00 -15.00 (Moscow time) at the IEC “Crocus Expo”, Moscow, Russia, Hall C. As places are limited at this open event, you are advised to sign up for it as soon as possible.
The seminar, which will feature guest speakers Dr Dimitri N Rylko, who is General Director of the Institute for Agricultural Market Studies (IKAR) and Dr Peter Plumstead, Associate Professor, Monogastric Nutrition at the University of Pretoria, will cover:
Axtra® PHY, the product around which the phytase research in Dr Plumstead’s talk will be based, is proven to deliver superior results when compared to best-in-class E. coli equivalents, including (at 2014 feed costs):
Johan Jansen-Storbacka, Regional Industry Leader, Danisco Animal Nutrition EMEA, commented ” We will be revealing new research at VIV Russia that helps producers maximise profitability and performance using our novel phytase, including new evidence that using doses higher than the industry standard of 500 FTU can enable producers to deliver broilers to market two and half days earlier. Producers will also be able to get answers to their specific questions on how best to use phytase.
In a separate talk at the VIV Russia Summit, Dr Peter Plumstead will look into the contribution that feed enzymes in general make to poultry gut health. Find out more about the agenda and how to sign up for this talk, which is part of a session held on 18 May between 14:30 – 15:30 at the Crystal Ballroom 2, Hotel Lotte, Moscow, on our website. All of the presentations given at VIV Russia will be available to download from our website after the show closes. Alternatively email us at firstname.lastname@example.org to receive PDF copies.
2/3 articles remaining | Register to continue reading.